Trydonis (beclometasone;formoterol;glycopyrronium bromide)

Region: 🇪🇺 EU
Active substance: beclometasone;formoterol;glycopyrronium bromide
Company: Chiesi Farmaceutici S.p.A.
Status: Authorised
Therapeutic area: Pulmonary Disease, Chronic Obstructive
EU approval: Thu 26 Apr 2018
Application: EMEA/H/C/004702
ATC: R03AL09
Official record: www.ema.europa.eu

Indication

Maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist (for effects on symptoms control and prevention of exacerbations see section 5.1).

Regulatory milestones

No milestones recorded in the last year.

Same substance in other markets

🇪🇺 Trimbow Authorised · Chiesi Farmaceutici S.p.A.

Follow Trydonis

Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.

Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.